Possible NAFLD name change must benefit both patients, field of hepatology

Regarding the nonalcoholic fatty liver disease nomenclature debate, I am pretty neutral to what the new name should be, and I want to be sensitive to all parties involved.There are some people who are passionate about changing the name and others who feel it should not change. Whatever we decide to do, it must be helpful to our patients and to the hepatology field. Currently, the No. 1 need our patients have is treatment for nonalcoholic steatohepatitis-related fibrosis. We have FDA and European Medicines Agency guidance that is linked to a particular natural history of disease and diagnosisRead More